A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma

BACKGROUND: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy. MATERIALS & METHODS: This was a retrospective review among eight medical centers comprising 100 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Cid, Jerónimo Rafael, Chards, Sonia Carrasco-Cara, González-Espinoza, Iván Romarico, García-Montes, Vanessa, Garibay-Díaz, Julio César, Hernández-Flores, Osvaldo, Riera-Sala, Rodrigo, Gozalishvili-Boncheva, Anna, Alatorre-Alexander, Jorge Arturo, Martínez-Barrera, Luis Manuel, Sánchez-Ríos, Carla Paola, Martinez-Camacho, Adriana, Martínez-Herrera, José Fabián, Guzmán-Casta, Jordi, Flores-Mariñelarena, Rodrigo Rafael, Diaz-Rico, Julián, Santillán-Doherty, Patricio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369526/
https://www.ncbi.nlm.nih.gov/pubmed/34408789
http://dx.doi.org/10.2217/lmt-2020-0027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369526/
https://www.ncbi.nlm.nih.gov/pubmed/34408789
http://dx.doi.org/10.2217/lmt-2020-0027

Ejemplares similares